Delivery of Virtual Care in Oncology: Province-Wide Interprofessional Consensus Statements Using a Modified Delphi Process.
consensus
telemedicine
teleoncology
virtual care
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
13 12 2021
13 12 2021
Historique:
received:
08
10
2021
revised:
05
12
2021
accepted:
08
12
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
31
12
2021
Statut:
epublish
Résumé
Virtual cancer care (i.e., teleoncology) was rapidly adopted during the COVID-19 pandemic to meet the needs of patients with cancer. However, there is a paucity of guidance for clinicians regarding virtual cancer care. We sought to develop consensus-based statements to guide the optimal provision of virtual care for clinicians caring for patients with cancer, using a modified Delphi consensus process with a 29-member panel consisting of an interprofessional group of clinicians caring for patients with cancer and patient representatives. The consensus process consisted of two rounds and one synchronous final consensus meeting. At the end of the modified Delphi process, 62 of 62 statements achieved consensus. Fifty-seven statements reached consensus in the first round of the process. Concerns regarding the ability to convey difficult news virtually and maintaining similar standards as in-person care without disproportionate strain on clinicians and patients were addressed in the consensus process. We achieved interprofessional consensus on virtual cancer care practices. Further research examining the impact of virtual cancer care on person-centred and clinical outcomes are needed to inform practices during the COVID-19 pandemic and beyond.
Identifiants
pubmed: 34940084
pii: curroncol28060445
doi: 10.3390/curroncol28060445
pmc: PMC8700064
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5332-5345Subventions
Organisme : CIHR
ID : 00420398
Pays : Canada
Références
J Natl Cancer Inst. 2011 Nov 2;103(21):1566-8
pubmed: 22010180
J Telemed Telecare. 1997;3(2):63-70
pubmed: 9206275
Curr Oncol. 2021 Sep 08;28(5):3488-3506
pubmed: 34590602
Am J Otolaryngol. 2019 Jan - Feb;40(1):83-88
pubmed: 30472134
JCO Oncol Pract. 2020 Aug;16(8):467-482
pubmed: 32401686
Cancer Discov. 2021 Feb;11(2):233-236
pubmed: 33355178
Intern Med J. 2012 Jul;42(7):780-5
pubmed: 21627743
Lancet Oncol. 2010 Feb;11(2):204-10
pubmed: 20152772
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA Oncol. 2021 Apr 1;7(4):597-602
pubmed: 33410867
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Intern Med J. 2013 May;43(5):581-4
pubmed: 23668268
J Natl Cancer Inst. 2021 Apr 6;113(4):371-380
pubmed: 33136163
Am Soc Clin Oncol Educ Book. 2018 May 23;38:540-545
pubmed: 30231354
Curr Oncol. 2021 Jan 22;28(1):671-677
pubmed: 33499380
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
J Telemed Telecare. 2015 Jun;21(4):181-8
pubmed: 25680389
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353
pubmed: 34337100
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
JCO Oncol Pract. 2020 Sep;16(9):527-529
pubmed: 32401684
JCO Oncol Pract. 2020 Jun;16(6):289-293
pubmed: 32364826
Intern Med J. 2014 Jan;44(1):101-3
pubmed: 24450527
PLoS One. 2011;6(6):e20476
pubmed: 21694759
JCO Glob Oncol. 2020 Sep;6:1461-1471
pubmed: 32997537
J Clin Oncol. 2012 Sep 1;30(25):3136-40
pubmed: 22778311
Med J Aust. 2015 Nov 16;203(10):406-6.e6
pubmed: 26561905